Display options
Cite
Chen X, Li C, Ewesuedo R, et al. Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin. Cancer Chemother Pharmacol. 2019;84(3):667doi: 10.1007/s00280-019-03890-7.
Chen, X., Li, C., Ewesuedo, R., & Yin, D. (2019). Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin. Cancer chemotherapy and pharmacology, 84(3), 667. https://doi.org/10.1007/s00280-019-03890-7
Chen, Xiaoying, et al. "Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin." Cancer chemotherapy and pharmacology vol. 84,3 (2019): 667. doi: https://doi.org/10.1007/s00280-019-03890-7
Chen X, Li C, Ewesuedo R, Yin D. Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin. Cancer Chemother Pharmacol. 2019 Sep;84(3):667. doi: 10.1007/s00280-019-03890-7. PMID: 31292683; PMCID: PMC6682847.
Copy Download .nbib Format: NLM
Share it on

Cancer Chemother Pharmacol. 2019 Sep;84(3):667. doi: 10.1007/s00280-019-03890-7.

Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin.

Cancer chemotherapy and pharmacology

Xiaoying Chen, Cheryl Li, Reginald Ewesuedo, Donghua Yin

Affiliations

  1. Early Oncology Development and Clinical Research, Pfizer Inc., 10777 Science Center Drive, San Diego, CA, 2121, USA. [email protected].
  2. Clinical Pharmacology/Pharmacometrics, Pfizer Essential Health Research and Development, Pfizer Inc, 300 Technology Square, Cambridge, MA, 02140, USA.
  3. Pfizer Essential Health, Biosimilars Clinical R&D, Pfizer Inc, 610 Main Street, Cambridge, MA, 02139, USA.
  4. Early Oncology Development and Clinical Research, Pfizer Inc., 10777 Science Center Drive, San Diego, CA, 2121, USA.

PMID: 31292683 PMCID: PMC6682847 DOI: 10.1007/s00280-019-03890-7

Abstract

The article "Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin

Publication Types